Business
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., received regulatory approval from ANVISA for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1 "Fostamatinib is an effective and well-tolerated new treat
About this update from Knight Therapeutics, Inc.
[{"type":"image","alt":"Knight Therapeutics","displaySize":"","headline":null,"caption":"Knight Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/evslWOsosdO5XPhhsPLtpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/evslWOsosdO5XPhhsPLtpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79}},"lazy":false},{"type":"text","content":"MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., received regulatory approval from ANVISA for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1","length":451,"tagName":"p"},{"type":"text","content":""Fostamatinib is an effective and well-tolerated new treatment option that addresses an unmet need in Brazil for ITP patients who have had an insufficient response to their treatment and remain at risk of bleeding,” said Dr. Ana Clara Kneese Nascimento, Professor at the Faculty of Medical Sciences of Santa Casa de São Paulo and hematologist responsible for the Platelet Outpatient Clinic of Santa Casa de São Paulo.","length":422,"tagName":"p"},{"type":"text","content":"“We are excited to receive the approval of TAVALISSE in Brazil. The approval of TAVALISSE not only provides a new treatment option with a different mechanism of action for adult patients with chronic ITP but also demonstrates Knight’s ability to address the complex regulatory requirements of the health agencies across all our countries,” said Samira Sakhia, President and CEO of Knight Therapeutics. “We expect the launch of TAVALISSE in Brazil in the second half of 2026.”","length":475,"tagName":"p"},{"type":"text","content":"Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to comm...